Testing a blood assay to predict Cytomegalovirus reactivation in Ulcerative Colitis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the QuantiFERON-CytoMegaloVirus (QF-CMV) assay, which measures the immune response to Cytomegalovirus (CMV) in blood samples, to predict the risk of CMV reactivation in patients with Ulcerative Colitis (UC). By comparing the QF-CMV results with traditional invasive biopsies that assess CMV DNA load, the study aims to develop a new algorithm for managing UC patients that could reduce unnecessary biopsies. If the QF-CMV assay is positive, it indicates protection against CMV reactivation, while a negative result would prompt further invasive testing. This approach could streamline patient care and improve treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with seropositive for CytoMegaloVirus (CMV) (IgG+)
* Patient requiring hospitalization for flare of Ulcerative Colitis (UC) with Mayo score \> 5 and an endoscopic subscore ≥ 2
* Social security affiliation
* Signed informed consent

Exclusion Criteria:

* Wardship patient and curatorial patient
* Patient unable to understand or sign the protocol
* Colectomy total or partial

Where it's running

• HCL-Hôpital Lyon Sud
  Lyon, France Recruiting
• Chu Saint-Etienne
  Saint-Etienne, France Recruiting

Study contacts

• Principal investigator: Xavier ROBLIN, MD PhD — Centre Hospitalier Universitaire de Saint Etienne
• Study coordinator: Xavier ROBLIN, MD PhD
• Email: xavier.roblin@chu-st-etienne.fr
• Phone: (0)477828119

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CMV-specific T cells after CMV reactivation in adults after HSCT

  This study tests CMV-specific immune recovery in adults who have their first CMV reactivation after an allogeneic HSCT to see how CMV-specific T cells change over time.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07688759

• Biomarkers linked to congenital CMV using newborn blood spots

  Researchers will test protein and RNA markers in dried blood spots from newborns to see if they can identify congenital CMV sequelae early.

  Recruiting at 2 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT07635368

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

• Family-donor viral CTLs plus standard care vs standard care alone for refractory ADV or CMV infection after stem cell transplant

  This study tests whether using family-donor virus-specific CTLs in addition to usual treatment helps children, teens, and young adults with hard-to-treat CMV or adenovirus infections after a stem cell transplant.

  Recruiting Phase 3 New York Medical College · Valhalla, New York and 1 other locations · NCT07225972

• CMV-specific immunoglobulin to prevent CMV problems in children getting allogeneic stem cell transplants

  Doctors will try giving CMV-specific immunoglobulin to children having allogeneic stem cell transplants to prevent CMV reactivation and related transplant complications.

  Recruiting University of Pisa · Trieste · NCT07013370

• R-MVST cell therapy for viral infections in children and young adults

  This will try giving rapidly generated virus-specific T cells (R-MVST) to children and young adults whose weakened immune systems have recurrent or treatment-resistant infections with EBV, CMV, adenovirus, or BK virus.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06926894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.